Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702319 | 1.00 | PFKFB3 (0.76) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL30702318 | 1.00 | PFKFB3 (0.76) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL894613 | 0.90 | POLB (0.82) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL4253424 | 0.88 | MEN1 (0.79) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL7366821 | 0.88 | AKR1C3 (0.67) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL5039358 | 0.87 | HDAC2 (0.71) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL5866753 | 0.87 | HDAC2 (0.71) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL787677 | 0.86 | PFKFB3 (1.00) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 | |
| SCHEMBL8251165 | 0.86 | PFKFB3 (0.67) | PFKFB3AKR1C3KMT2AMEN1POLB | |
| SCHEMBL400223 | 0.86 | THRB (0.83) | PFKFB3HDAC2HDAC8HDAC6AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | UNIVERSITÄTSMEDIZIN GREIFSWALD (DE) | 2025-12-04 | — | — | US | claimed |
| EP-4292591-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | Universitätsmedizin Greifswald (DE) | 2023-12-20 | — | — | EP | claimed |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | UNIVERSITÄTSMEDIZIN GREIFSWALD (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4539835-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | Universitätsmedizin Greifswald (DE) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023242278-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | UNIVERSITÄTSMEDIZIN GREIFSWALD (DE) | 2023-12-21 | — | — | WO | disclosed |
| EP-4292591-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | Universitätsmedizin Greifswald (DE) | 2023-12-20 | — | — | EP | disclosed |
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| CN-106146361-A | Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use | 四川大学 | 2016-11-23 | — | — | CN | disclosed |
| CN-105985265-A | Indene-1-subunit sulfonyl benzoyl hydrazine derivative as well as preparation method and application thereof | 四川大学 | 2016-10-05 | — | — | CN | disclosed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-20070151479-A1 | Acidic monoazo dyestuffs | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-07-05 | — | — | US | disclosed |
| US-20070151479-A1 | Acidic monoazo dyestuffs | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-07-05 | — | — | US | disclosed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | PFKFB3 3003/4885HDAC2 1449/4885HDAC8 475/4885 |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | PFKFB3 4292/4885HDAC2 2688/4885HDAC8 1707/4885 |
| US-20070151479-A1 | Acidic monoazo dyestuffs | PAH, TYR, CD68 | PFKFB3 712/4885HDAC2 1919/4885HDAC8 1139/4885 |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | REN, SLC10A1, GLS | PFKFB3 262/4885HDAC2 1062/4885HDAC8 1326/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | PFKFB3 4292/4885HDAC2 2688/4885HDAC8 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.